NASDAQ:NRXS NeurAxis 11/12/2024 Earnings Results & Report $7.74 +1.21 (+18.53%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$7.78 +0.04 (+0.52%) As of 10/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NeurAxis reported earnings on November 12, 2024. The company reported EPS of -$0.25, while revenue was $0.67 million. Research:ProfileForecast Earnings Announcement Details Report DateNovember 12, 2024TimeBefore Market Opens NeurAxis EPS ResultsActual EPS-$0.25Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANeurAxis Revenue ResultsActual Revenue$0.67 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNeurAxis' next earnings date is estimated for Monday, November 9, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile NeurAxis Earnings FAQ Did NeurAxis beat earnings estimates for the quarter? NeurAxis (NASDAQ:NRXS) reported earnings of -$0.25 per share for the quarter. The report was announced on Tuesday, November 12, 2024. What was NeurAxis' revenue for the quarter? NeurAxis reported revenue of $0.67 million for the quarter. When is NeurAxis' next earnings date? NeurAxis' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for NeurAxis on the company's earnings history page. NeurAxis Earnings HeadlinesAetna deems IB-Stim by NeurAxis medically necessaryOctober 15 at 1:32 PM | tipranks.comNeurAxis Announces Major National Insurer Coverage Expansion for IB-Stim Penetrating 26 Million Medical Plan MembersOctober 15 at 9:31 AM | quiverquant.comQFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered LivesOctober 15 at 9:18 AM | globenewswire.comNeurAxis Declares Q3 Stock Dividend on Preferred SharesOctober 14 at 5:31 PM | tipranks.comNovoCure (NASDAQ:NVCR) versus NeurAxis (NASDAQ:NRXS) Head-To-Head AnalysisOctober 12, 2026 | americanbankingnews.comSee More NeurAxis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeurAxis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeurAxis and other key companies, straight to your email. Email Address About NeurAxisNeurAxis (NASDAQ:NRXS) is a medical technology company focused on developing and commercializing neuromodulation therapies for functional gastrointestinal disorders. The company’s primary product is IB-Stim, a minimally invasive device that delivers percutaneous electrical nerve field stimulation through the external ear. IB-Stim is designed to modulate neural pathways associated with functional abdominal pain and related gastrointestinal symptoms. It has been cleared by the U.S. Food and Drug Administration for use in patients, including adolescents, with functional abdominal pain associated with irritable bowel syndrome. The therapy is administered by qualified healthcare professionals and is intended to complement broader clinical care. NeurAxis is headquartered in Carmel, Indiana, and primarily serves the U.S. healthcare market through physicians and other medical providers. The company’s activities center on expanding awareness and adoption of its neuromodulation platform in gastroenterology, pain management and related specialties.View NeurAxis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
